Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 14.58.
Forward PE Ratio (14.58) = Close Price ($50.90) / Consensus Forward EPS ($3.58)
FORWARD PE RATIO
14.58
SECTOR MEDIAN · HEALTHCARE
20.09
median of 67 covered companies
CURRENT VS SECTOR MEDIAN
-27.43%
vs the sector median at left
GSK plc
Market Cap
$101.98B
Forward PE Ratio
14.58
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| GSK plc (GSK) | $101.98B | 14.58 |
| McKesson Corporation (MCK)vs › | $105.58B | 22.55 |
| HCA Healthcare, Inc. (HCA)vs › | $89.08B | 14.00 |
| Medtronic plc (MDT)vs › | $116.07B | 16.20 |
| Elevance Health Inc. (ELV)vs › | $84.66B | 14.66 |
| CVS Health Corp. (CVS)vs › | $119.30B | 12.50 |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $82.11B | 15.35 |
| Boston Scientific Corporation (BSX)vs › | $76.09B | 15.28 |
| Bristol-Myers Squibb Company (BMY)vs › | $129.94B | 9.62 |
| Cigna Corporation (CI)vs › | $72.37B | 9.14 |
Trailing P/E
16.5
reported TTM EPS
Forward P/E
14.6
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $3.58 implies +13.3% EPS growth vs the reported trailing $3.16.
At today's $50.90 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $3.58 | $3.51 – $3.67 | 6 | 14.2x |
| 2027-12-31 | $3.88 | $3.68 – $4.10 | 6 | 13.1x |
| 2028-12-31 | $4.09 | $3.73 – $4.52 | 9 | 12.4x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
